Entry - #607676 - IMMUNODEFICIENCY 67; IMD67 - OMIM - (MIRROR)
# 607676

IMMUNODEFICIENCY 67; IMD67


Alternative titles; symbols

IRAK4 DEFICIENCY; IKAK4D
INVASIVE PNEUMOCOCCAL DISEASE, RECURRENT ISOLATED; IPD


Other entities represented in this entry:

INVASIVE PNEUMOCOCCAL DISEASE, PROTECTION AGAINST, INCLUDED

Phenotype-Gene Relationships

Location Phenotype Phenotype
MIM number
Inheritance Phenotype
mapping key
Gene/Locus Gene/Locus
MIM number
12q12 Immunodeficiency 67 607676 AR 3 IRAK4 606883
Clinical Synopsis
 
Phenotypic Series
 

INHERITANCE
- Autosomal recessive
NEUROLOGIC
Central Nervous System
- Bacterial meningitis
METABOLIC FEATURES
- No or attenuated fever
IMMUNOLOGY
- Recurrent invasive bacterial infections
- Streptococcus pneumonia
- Staphylococcus aureus
- Pseudomonas aeruginosa
- Mycobacteria
- Impaired cytokine response to LPS, certain TLRs, and IL1B
- Impaired antibody response to pneumococcal vaccination
- Neutropenia
- Normal Ig levels
- Variable Ig levels (in some patients)
- Normal B cells
- Normal T cells
- Normal NK cells
PRENATAL MANIFESTATIONS
Placenta & Umbilical Cord
- Delayed umbilical cord separation
LABORATORY ABNORMALITIES
- Increased C-reactive protein
- Increased ESR
MISCELLANEOUS
- Onset in infancy or early childhood
- Bacterial meningitis is often an initial infection
- High death rate before age 8 years
- The disease tends to abate with age
- Treatment with IVIg or prophylactic antibiotics may be beneficial
MOLECULAR BASIS
- Caused by mutation in the interleukin 1 receptor-associated kinase 4 gene (IRAK4, 606883.0001)
Immunodeficiency (select examples) - PS300755 - 137 Entries
Location Phenotype Inheritance Phenotype
mapping key
Phenotype
MIM number
Gene/Locus Gene/Locus
MIM number
1p36.33 Immunodeficiency 38 AR 3 616126 ISG15 147571
1p36.33 ?Immunodeficiency 16 AR 3 615593 TNFRSF4 600315
1p36.23 Immunodeficiency 109 with lymphoproliferation AR 3 620282 TNFRSF9 602250
1p36.22 Immunodeficiency 14A, autosomal dominant AD 3 615513 PIK3CD 602839
1p36.22 Immunodeficiency 14B, autosomal recessive AR 3 619281 PIK3CD 602839
1p35.2 Immunodeficiency 22 AR 3 615758 LCK 153390
1p34.2 Immunodeficiency 24 AR 3 615897 CTPS1 123860
1p22.3 ?Immunodeficiency 37 AR 3 616098 BCL10 603517
1q21.3 Immunodeficiency 42 AR 3 616622 RORC 602943
1q23.3 Immunodeficiency 20 AR 3 615707 FCGR3A 146740
1q24.2 ?Immunodeficiency 25 AR 3 610163 CD247 186780
1q25.3 Immunodeficiency 133 with autoimmunity and autoinflammation AR 3 620565 ARPC5 604227
1q25.3 Immunodeficiency 70 AD 3 618969 IVNS1ABP 609209
1q31.3-q32.1 Immunodeficiency 105, severe combined AR 3 619924 PTPRC 151460
2p16.1 Immunodeficiency 92 AR 3 619652 REL 164910
2p11.2 Immunodeficiency 116 AR 3 608957 CD8A 186910
2q11.2 Immunodeficiency 48 AR 3 269840 ZAP70 176947
2q24.2 Immunodeficiency 95 AR 3 619773 IFIH1 606951
2q32.2 Immunodeficiency 31A, mycobacteriosis, autosomal dominant AD 3 614892 STAT1 600555
2q32.2 Immunodeficiency 31B, mycobacterial and viral infections, autosomal recessive AR 3 613796 STAT1 600555
2q32.2 Immunodeficiency 31C, chronic mucocutaneous candidiasis, autosomal dominant AD 3 614162 STAT1 600555
2q33.2 ?Immunodeficiency 123 with HPV-related verrucosis AR 3 620901 CD28 186760
2q35 Immunodeficiency 124, severe combined AR 3 611291 NHEJ1 611290
3p22.2 Immunodeficiency 68 AR 3 612260 MYD88 602170
3q21.3 Immunodeficiency 21 AD 3 614172 GATA2 137295
3q29 Immunodeficiency 46 AR 3 616740 TFRC 190010
4q24 Immunodeficiency 75 AR 3 619126 TET2 612839
4q35.1 {Immunodeficiency 83, susceptibility to viral infections} AD, AR 3 613002 TLR3 603029
5p15.2 {Immunodeficiency 107, susceptibility to invasive staphylococcus aureus infection} AD 3 619986 OTULIN 615712
5p13.2 Immunodeficiency 104, severe combined AR 3 608971 IL7R 146661
5q11.2 ?Immunodeficiency 94 with autoinflammation and dysmorphic facies AD 3 619750 IL6ST 600694
5q13.1 Immunodeficiency 36 AD 3 616005 PIK3R1 171833
5q31.1 Immunodeficiency 93 and hypertrophic cardiomyopathy AR 3 619705 FNIP1 610594
5q31.1 Immunodeficiency 117, mycobacteriosis, autosomal recessive AR 3 620668 IRF1 147575
5q33.3 Immunodeficiency 29, mycobacteriosis AR 3 614890 IL12B 161561
5q35.1 Immunodeficiency 40 AR 3 616433 DOCK2 603122
5q35.1 Immunodeficiency 81 AR 3 619374 LCP2 601603
6p25.2 Immunodeficiency 57 with autoinflammation AR 3 618108 RIPK1 603453
6p21.33 ?Immunodeficiency 127 AR 3 620977 TNF 191160
6p21.31 Immunodeficiency 87 and autoimmunity AR 3 619573 DEF6 610094
6p21.1 Immunodeficiency 126 AR 3 620931 PTCRA 606817
6q14.1 Immunodeficiency 23 AR 3 615816 PGM3 172100
6q15 Immunodeficiency 60 and autoimmunity AD 3 618394 BACH2 605394
6q23.3 Immunodeficiency 27B, mycobacteriosis, AD AD 3 615978 IFNGR1 107470
6q23.3 Immunodeficiency 27A, mycobacteriosis, AR AR 3 209950 IFNGR1 107470
7p22.2 Immunodeficiency 11A AR 3 615206 CARD11 607210
7p22.2 Immunodeficiency 11B with atopic dermatitis AD 3 617638 CARD11 607210
7q22.1 Immunodeficiency 71 with inflammatory disease and congenital thrombocytopenia AR 3 617718 ARPC1B 604223
7q22.3 Immunodeficiency 97 with autoinflammation AR 3 619802 PIK3CG 601232
8p11.21 Immunodeficiency 15A AD 3 618204 IKBKB 603258
8p11.21 Immunodeficiency 15B AR 3 615592 IKBKB 603258
8q11.21 Immunodeficiency 26, with or without neurologic abnormalities AR 3 615966 PRKDC 600899
8q11.21 Immunodeficiency 54 AR 3 609981 MCM4 602638
9q22.2 Immunodeficiency 82 with systemic inflammation AD 3 619381 SYK 600085
9q34.3 Immunodeficiency 103, susceptibility to fungal infection AR 3 212050 CARD9 607212
10p15.1 Immunodeficiency 41 with lymphoproliferation and autoimmunity AR 3 606367 IL2RA 147730
10p13 Immunodeficiency 80 with or without cardiomyopathy AR 3 619313 MCM10 609357
11p15.5 ?Immunodeficiency 39 AR 3 616345 IRF7 605047
11p15.4 Immunodeficiency 10 AR 3 612783 STIM1 605921
11q12.1 Immunodeficiency 77 AD 3 619223 MPEG1 610390
11q13.3 Immunodeficiency 90 with encephalopathy, functional hyposplenia, and hepatic dysfunction AR 3 613759 FADD 602457
11q13.4 Immunodeficiency 122 AR 3 620869 POLD3 611415
11q23.3 Immunodeficiency 18, SCID variant AR 3 615615 CD3E 186830
11q23.3 Immunodeficiency 18 AR 3 615615 CD3E 186830
11q23.3 Immunodeficiency 19, severe combined AR 3 615617 CD3D 186790
11q23.3 Immunodeficiency 17, CD3 gamma deficient AR 3 615607 CD3G 186740
11q23.3 ?Immunodeficiency 59 and hypoglycemia AR 3 233600 HYOU1 601746
12p13.31 Immunodeficiency 79 AR 3 619238 CD4 186940
12q12 Immunodeficiency 67 AR 3 607676 IRAK4 606883
12q13.13-q13.2 Immunodeficiency 72 with autoinflammation AR 3 618982 NCKAP1L 141180
12q13.3 Immunodeficiency 44 AR 3 616636 STAT2 600556
12q15 ?Immunodeficiency 69, mycobacteriosis AR 3 618963 IFNG 147570
12q24.13 Immunodeficiency 100 with pulmonary alveolar proteinosis and hypogammaglobulinemia AD 3 618042 OAS1 164350
12q24.31 Immunodeficiency 9 AR 3 612782 ORAI1 610277
13q33.1 Immunodeficiency 78 with autoimmunity and developmental delay AR 3 619220 TPP2 190470
14q11.2 Immunodeficiency 7, TCR-alpha/beta deficient AR 3 615387 TRAC 186880
14q11.2 ?Immunodeficiency 108 with autoinflammation AR 3 260570 CEBPE 600749
14q12 Immunodeficiency 115 with autoinflammation AR 3 620632 RNF31 612487
14q12 Immunodeficiency 65, susceptibility to viral infections AR 3 618648 IRF9 147574
14q32.2 Immunodeficiency 49, severe combined AD 3 617237 BCL11B 606558
15q14 Immunodeficiency 64 AR 3 618534 RASGRP1 603962
15q21.1 Immunodeficiency 43 AR 3 241600 B2M 109700
15q21.2 Immunodeficiency 86, mycobacteriosis AR 3 619549 SPPL2A 608238
16p12.1 Immunodeficiency 56 AR 3 615207 IL21R 605383
16p11.2 Immunodeficiency 52 AR 3 617514 LAT 602354
16p11.2 Immunodeficiency 8 AR 3 615401 CORO1A 605000
16q22.1 Immunodeficiency 58 AR 3 618131 CARMIL2 610859
16q22.1 Immunodeficiency 121 with autoinflammation AD 3 620807 PSMB10 176847
16q24.1 Immunodeficiency 32A, mycobacteriosis, autosomal dominant AD 3 614893 IRF8 601565
16q24.1 Immunodeficiency 32B, monocyte and dendritic cell deficiency, autosomal recessive AR 3 226990 IRF8 601565
17q11.2 ?Immunodeficiency 13 AD 3 615518 UNC119 604011
17q12-q21.1 ?Immunodeficiency 84 AD 3 619437 IKZF3 606221
17q21.31 Immunodeficiency 112 AR 3 620449 MAP3K14 604655
17q21.32 ?Immunodeficiency 88 AR 3 619630 TBX21 604895
18q21.32 Immunodeficiency 12 AR 3 615468 MALT1 604860
19p13.3 Hatipoglu immunodeficiency syndrome AR 3 620331 DPP9 608258
19p13.2 Immunodeficiency 35 AR 3 611521 TYK2 176941
19p13.11 Immunodeficiency 76 AR 3 619164 FCHO1 613437
19p13.11 Immunodeficiency 30 AR 3 614891 IL12RB1 601604
19q13.2 ?Immunodeficiency 62 AR 3 618459 ARHGEF1 601855
19q13.32 ?Immunodeficiency 53 AR 3 617585 RELB 604758
19q13.33 Immunodeficiency 96 AR 3 619774 LIG1 126391
19q13.33 ?Immunodeficiency 125 AR 3 620926 FLT3LG 600007
19q13.33 Immunodeficiency 120 AR 3 620836 POLD1 174761
20p11.23 ?Immunodeficiency 101 (varicella zoster virus-specific) AD 3 619872 POLR3F 617455
20p11.21 Immunodeficiency 55 AR 3 617827 GINS1 610608
20q11.23 ?Immunodeficiency 99 with hypogammaglobulinemia and autoimmune cytopenias AR 3 619846 CTNNBL1 611537
20q13.12 T-cell immunodeficiency, recurrent infections, autoimmunity, and cardiac malformations AR 3 614868 STK4 604965
20q13.13 Immunodeficiency 91 and hyperinflammation AR 3 619644 ZNFX1 618931
21q22.11 Immunodeficiency 45 AR 3 616669 IFNAR2 602376
21q22.11 Immunodeficiency 106, susceptibility to viral infections AR 3 619935 IFNAR1 107450
21q22.11 Immunodeficiency 28, mycobacteriosis AR 3 614889 IFNGR2 147569
21q22.3 ?Immunodeficiency 119 AR 3 620825 ICOSLG 605717
21q22.3 Immunodeficiency 114, folate-responsive AR 3 620603 SLC19A1 600424
22q11.1 Immunodeficiency 51 AR 3 613953 IL17RA 605461
22q12.3 ?Immunodeficiency 85 and autoimmunity AD 3 619510 TOM1 604700
22q12.3 Immunodeficiency 63 with lymphoproliferation and autoimmunity AR 3 618495 IL2RB 146710
22q13.1 ?Immunodeficiency 73C with defective neutrophil chemotaxis and hypogammaglobulinemia AR 3 618987 RAC2 602049
22q13.1 Immunodeficiency 73B with defective neutrophil chemotaxis and lymphopenia AD 3 618986 RAC2 602049
22q13.1 Immunodeficiency 73A with defective neutrophil chemotaxix and leukocytosis AD 3 608203 RAC2 602049
22q13.1 ?Immunodeficiency 89 and autoimmunity AR 3 619632 CARD10 607209
22q13.1-q13.2 ?Immunodeficiency 66 AR 3 618847 MKL1 606078
Xp22.2 Immunodeficiency 74, COVID19-related, X-linked XLR 3 301051 TLR7 300365
Xp22.2 Immunodeficiency 98 with autoinflammation, X-linked SMo, XL 3 301078 TLR8 300366
Xp22.12 ?Immunodeficiency 61 XLR 3 300310 SH3KBP1 300374
Xp21.1-p11.4 Immunodeficiency 34, mycobacteriosis, X-linked XLR 3 300645 CYBB 300481
Xp11.23 Wiskott-Aldrich syndrome XLR 3 301000 WAS 300392
Xq12 Immunodeficiency 50 XLR 3 300988 MSN 309845
Xq13.1 Severe combined immunodeficiency, X-linked XLR 3 300400 IL2RG 308380
Xq13.1 Combined immunodeficiency, X-linked, moderate XLR 3 312863 IL2RG 308380
Xq22.1 Agammaglobulinemia, X-linked 1 XLR 3 300755 BTK 300300
Xq24 Immunodeficiency 118, mycobacteriosis XLR 3 301115 MCTS1 300587
Xq25 Lymphoproliferative syndrome, X-linked, 1 XLR 3 308240 SH2D1A 300490
Xq26.1 Immunodeficiency 102 XLR 3 301082 SASH3 300441
Xq26.3 Immunodeficiency, X-linked, with hyper-IgM XLR 3 308230 TNFSF5 300386
Xq28 Immunodeficiency 47 XLR 3 300972 ATP6AP1 300197
Xq28 Immunodeficiency 33 XLR 3 300636 IKBKG 300248

TEXT

A number sign (#) is used with this entry because of evidence that immunodeficiency-67 (IMD67) is caused by homozygous or compound heterozygous mutation in the gene encoding interleukin-1 receptor-associated kinase-4 (IRAK4; 606883) on chromosome 12q12.


Description

Immunodeficiency-67 (IMD67) is an autosomal recessive primary immunodeficiency characterized by recurrent severe systemic and invasive bacterial infections beginning in infancy or early childhood. The most common organisms implicated are Streptococcus pneumoniae and Staphylococcus aureus; Pseudomonas and atypical Mycobacteria may also be observed. IMD67 is life-threatening in infancy and early childhood. The first invasive infection typically occurs before 2 years of age, with meningitis representing up to 41% of the bacterial infections. The mortality rate in early childhood is high, with most deaths occurring before 8 years of age. Affected individuals have an impaired inflammatory response to infection, including lack of fever and neutropenia, although erythrocyte sedimentation rate (ESR) and C-reactive protein may be elevated. General immunologic workup tends to be normal, with normal levels of B cells, T cells, and NK cells. However, more detailed studies indicate impaired cytokine response to lipopolysaccharide (LPS) and IL1B (147720) stimulation; response to TNFA (191160) is usually normal. Patients have good antibody responses to most vaccinations, with the notable exception of pneumococcal vaccination. Viral, fungal, and parasitic infections are not generally observed. Early detection is critical in early childhood because prophylactic treatment with IVIg or certain antibiotics is effective; the disorder tends to improve naturally around adolescence. At the molecular level, the disorder results from impaired function of selective Toll receptor (see TLR4, 603030)/IL1R (see IL1R1, 147810) signaling pathways that ultimately activate NFKB (164011) to produce cytokines (summary by Ku et al., 2007; Picard et al., 2010; Grazioli et al., 2016).

See also IMD68 (612260), caused by mutation in the MYD88 gene (602170), which shows a similar phenotype to IMD67. As the MYD88 and IRAK4 genes interact in the same intracellular signaling pathway, the clinical and cellular features are almost indistinguishable (summary by Picard et al., 2010).


Clinical Features

Kuhns et al. (1997) reported a 15-year-old girl with a history of recurrent infections since early childhood. She did not have delayed separation of the umbilical cord at birth. Her infections, which were associated with minimal or no febrile response and persistent neutropenia, included pneumococcal meningitis, Neisseria, and Staphylococcus aureus, as well as other infections. She had poor response to LPS and IL1B, but normal response to TNFA, in vivo and in vitro, suggesting a defect in an upstream signaling pathway. In a follow-up report of this patient, Medvedev et al. (2003) noted that her clinical manifestations improved after adolescence.

Haraguchi et al. (1998) described a 3-year-old girl, born of an incestuous relationship, who presented in infancy with recurrent severe infections, including cellulitis, lymphadenitis, septic arthritis, and sepsis due to Staphylococcus aureus and pneumococcus. She did not have fever. Detailed immunologic workup showed deficient production of IL12 (see IL12B, 161561). The patient's peripheral blood mononuclear cells (PBMCs) exhibited normal proliferative responses to antigens and normal immune responses, including in vivo production of antibodies to diphtheria, tetanus, and pneumococcal antigens. Immunoglobulin levels and B-cell and T-cell phenotypes were also normal. In contrast, IL12 p70 heterodimer production was undetectable by using supernatants of the patient's stimulated PBMCs when compared with control cells treated similarly. Although present, IFNG (147570) was reduced, and patient cells did not produce IL12 in response to recombinant IFNG, Staphylococcus aureus, or LPS. Patient cells were able to produce IL2 (147680), IL6 (147620), TNFA (191160), and IFNG after appropriate stimulation. The findings suggested either a defect in the signaling pathways for the activation of IL12B gene expression or an abnormality in IL12B itself.

Picard et al. (2003) described 3 unrelated children, including the child originally reported by Haraguchi et al. (1998), with recurrent infections and poor inflammatory response in whom extracellular, pyogenic bacteria were the only microorganisms responsible for infection. Gram-positive Streptococcus pneumoniae and Staphylococcus aureus were the most frequently found and were the only pathogens identified in 2 patients. Infections began early in life but became less frequent with age, and the patients were well with no treatment at ages 6, 11, and 7 years. All known primary immunodeficiencies were excluded. In particular, the patients had normal serum antibody titers against protein and polysaccharide antigens, including those from S. pneumoniae. None of the patients' monocytes responded to LPS; however, they responded normally to TNF-alpha (191160). The patients did not respond to IL1B, IL18 (600953), or any of the TLR1-6 (see 601194) or TLR9 (605474) ligands, as assessed by activation of NF-kappa-B (see 164011) and p38-MAPK (600289) and induction of IL1B IL6, IL12, TNFA, and IFNG.

In a follow-up of the patients reported by Picard et al. (2003), Day et al. (2004) found that 2 continued to do well, but 1, an 8-year-old girl, was unable to sustain antibody responses to polysaccharide or protein antigens or to a neoantigen-bacteriophage. She continued to have recurring bacterial and fungal infections, eventually requiring intravenous immunoglobulin therapy. They recommended testing for IRAK4 deficiency in patients with recurrent bacterial and fungal infections without sustained antibody response to immunization.

Enders et al. (2004) reported 2 sibs, born of consanguineous Turkish parents, with IMD67. They presented in infancy with recurrent infections, including bronchitis, gastroenteritis, osteomyelitis, and pneumococcal meningitis. Despite treatment, both died, at 14 and 2 months of age. During the infections, both children had a poor inflammatory response without fever, suggesting a deficiency in NFKB-mediated immunity.

Takada et al. (2006) reported 2 Japanese sibs with IMD67. Both had delayed separation of the umbilical cord at 34 to 39 days after birth. The older sib presented in the first years of life with recurrent pneumococcal meningitis and arthritis, which was fatal at age 2. Basic immunologic studies were unremarkable, and he had received several vaccinations without adverse effect; he did not receive pneumococcal vaccination. The younger brother had no apparent infection at 5 months of age. However, in vitro studies showed that patient mononuclear cells had defective IL6 and TNFA production in response to LPS and IL1B. Flow cytometric studies showed impaired intracellular TNFA production in response to LPS, which the authors suggested could be used as a screening method. Takada et al. (2016) reported follow-up of this family, noting that the younger brother from the first report and another affected brother, both of whom had the disorder, had not had invasive bacterial infections due to antimicrobial prophylaxis since early infancy after the diagnosis.

Ku et al. (2007) reported a 7-year-old boy, born to unrelated Hungarian parents, with IMD67. He had routine immunizations with no complications. At age 3 years, he presented with arthritis of the right hip due to pneumococcal infection, followed by pneumococcal meningitis at age 5. During these episodes, he had either no fever or a low-grade fever and low white blood cell counts, indicating a poor inflammatory response. ESR and C-reactive protein were increased. Immunologic workup was essentially normal, although he failed to mount a good antibody response to pneumococcal vaccination; responses to other vaccinations were normal. He had no other bacterial, fungal, or viral infections. Patient cells showed impaired IL6 production in response to IL1B and LPS compared to controls, although response to TNFA was normal. These findings suggested a defect in the TLR (see 603030)-NFKB (see 164011) signaling pathway.

Lavine et al. (2007) reported 3 sibs with IMD67. The first child died at age 5 months due to septic shock associated with Staphylococcus aureus meningitis. The other 2 sibs, who were twins, had recurrent severe systemic infections since early childhood, mainly due to pneumococcus, but also Pseudomonas and atypical Mycobacterium. Both twins had delayed or attenuated signs of inflammation, such as absence of fever and persistent neutropenia. They were treated with IVIg until about age 18 years, but did not have recurrence of the infections as young adults. Immunologic studies showed impaired IL6 production in response to LPS or IL1B compared to controls. There was also some evidence of T-cell dysfunction, including low numbers of CD3+ T cells and variably impaired proliferative responses to antigens. There was a normal antibody response to most vaccinations, but not to pneumococcal vaccine. These findings indicated defects in both the adaptive and innate immune systems, and also suggested that the condition may improve with age.

Ku et al. (2007) reported 28 patients with IMD67. Many of the patients had previously been reported. Most patients developed invasive and often recurrent pneumococcal disease in childhood, but other infections, except for severe Staphylococcal disease, were rare. Although nearly half of the patients died, death occurred only in patients 8 years old and younger. Older patients tended to have remission of the disease. Detailed analysis of patient leukocyte subsets showed that only the TLR3 agonist poly(I:C) could induce production of 11 non-IFN cytokines. The TLR4 agonist, LPS, could induce some responses in myeloid dendritic cells and monocyte-derived dendritic cells. The TLR3 (603029)- and TLR4-interferon-alpha (IFNA; 147660)/beta (IFNB; 147640) pathways were not impaired. Ku et al. (2007) concluded that IRAK4-dependent TLRs and IL1Rs are vital for childhood immunity to pyogenic bacteria, particularly S. pneumoniae, but they are not essential for protective immunity to most infections.

Hoarau et al. (2007) reported a 14-year-old French boy, born of unrelated patients, with IRAK4 deficiency characterized by recurrent infections, osteomyelitis, and cellulitis beginning at age 15 days. Apart from elevated C-reactive protein (CRP; 123260) and very low neutrophil numbers, his immunologic status was normal.

Picard et al. (2010) reported and reviewed the features of 48 patients from 31 kindreds with IMD67, including 36 previously reported patients and 12 new patients. The families originated from several countries; 5 families were consanguineous. In general, immunologic investigations showed normal T and B lymphocytes, NK cells, monocytes, dendritic cells, and Ig levels, although some patients had relatively high levels of certain Ig subsets. These patients had good antibody responses to most vaccinations, although about half had poor response to pneumococcal antigen. Most patients developed early-onset invasive bacterial infections, including meningitis, sepsis, arthritis, osteomyelitis, and deep tissue abscesses. Noninvasive cutaneous or upper respiratory infections were also observed. The most common organisms were Streptococcal pneumoniae, Staphylococcus aureus, and Pseudomonas aeruginosa. Less common organisms included H. influenzae, Shigella, and Neisseria. Affected individuals had an impaired inflammatory response, manifest as poor or absent fever and low leukocyte and neutrophil levels; C-reactive protein levels were variable. Functional studies of patient cells show impaired cytokine responses to TLR and IL1R agonists, with, for example, low IL6 and low TNFA production. Many died of the disease, all before 8 years of age, and most before 2 years. Prophylactic treatment with antibiotics and IVIg was beneficial for survival. Clinical status and outcome improved with age, particularly around adolescence. Picard et al. (2010) noted the narrow susceptibility to certain bacterial infections and emphasized that early diagnosis is critical to initiate treatment.

Grazioli et al. (2016) reported 2 sisters, born of unrelated European Canadian parents, with IMD67 manifest as severe invasive pneumococcal meningitis resulting in death at 2 and 3 years of age. They both had routine immunizations early in life, normal immune cell levels, and no fever during the infections, indicating poor inflammatory responses.

Takada et al. (2016) reported 10 Japanese patients from 6 unrelated families with IMD67. One of the families had previously been reported (Takada et al., 2006); the sibs in that family were treated early and did not have invasive infections. The other 8 patients had severe invasive bacterial infections before the age of 4 years. Seven of them had pneumococcal meningitis, and 5 died of the infection despite early intervention with antibiotic therapy. Four patients had delayed separation of the umbilical cord (later than 21 days). Laboratory studies showed no apparent abnormalities in serum Ig levels, lymphocyte subsets, NK activity, or lymphocyte proliferative response against PHA. However, the patients studied had decreased TNFA production from stimulated monocytes.


Inheritance

The transmission pattern of IMD67 in the families reported by Picard et al. (2003) was consistent with autosomal recessive inheritance.


Molecular Genetics

In 3 patients with IMD67, Picard et al. (2003) identified homozygous loss-of-function mutations in the IRAK4 gene (see 606883.0001-606883.0002). In each case, the mutations were associated with complete deficiency for the kinase. One of the patients was originally reported by Haraguchi et al. (1998).

In a 15-year-old girl with IMD67 (Kuhns et al., 1997), Medvedev et al. (2003) identified compound heterozygous mutations in the IRAK4 gene (606883.0002 and 606883.0003). Both mutations resulted in proteins with intact death domains but truncated kinase domains, precluding expression of full-length IRAK4 and conferring a recessive phenotype.

In a patient, born of consanguineous Turkish parents, with IMD67, Enders et al. (2004) identified a homozygous frameshift mutation (c.573delA; 606883.0008) in the IRAK4 gene. No material was available for further analysis, but the mutation segregated with the disorder in the family. A similarly affected sib had died of the disease, but no DNA from this sib was available.

In 2 Japanese sibs with IMD67, Takada et al. (2006) identified a homozygous frameshift mutation in the IRAK4 gene (606883.0009). The mutation segregated with the disorder in the family.

In a 7-year-old boy born of unrelated Hungarian parents, Ku et al. (2007) found that IMD67 was related to compound heterozygosity for 2 mutations in the IRAK4 gene, located in intron 10 (c.1189-1G-T, 606883.0004 and c.1188+520A-G, 606883.0005). The authors noted that this patient was the first in whom noncoding mutations in the IRAK4 gene had been found.

In 2 sibs with IMD67, Lavine et al. (2007) identified a homozygous nonsense mutation in the IRAK4 gene (Q293X; 606883.0002). The mutation segregated with the disorder in the family.

In a 14-year-old French boy with IMD67, Hoarau et al. (2007) identified compound heterozygous mutations in the IRAK4 gene (see 606883.0006 and 606883.0007). Stimulation of the patient's PMNs with TLR agonists revealed the absence of IRAK1 (300283) phosphorylation and impaired PMN responses. However, responses to the TLR9 agonist CpG were normal, except for cytokine production. Impairment of TLR9 responses was observed after pretreatment with PI3K (see 601232) inhibitors. Hoarau et al. (2007) proposed that there may be an alternative TLR9 pathway leading to PI3K activation independently of the classical MYD88 (602170)-IRAK4 pathway. They suggested that this alternative pathway may play a role in control of infections by microorganisms other than pyogenic bacteria in patients with IRAK4 deficiency.

In 9 patients from 5 unrelated Japanese families with IMD67, Takada et al. (2016) identified a homozygous frameshift mutation in the IRAK4 gene (606883.0009). Another affected Japanese patient (patient 4) was compound heterozygous for that mutation and a nonsense mutation. The findings suggested that the frameshift mutation is a founder mutation in the Japanese population.


Pathogenesis

By studying responses to the TLR4 ligand, LPS, and to the bacterial chemoattractant, fMLP, in PMNs from 1 patient with IRAK4 deficiency and 3 patients with NEMO (300248) deficiency causing X-linked hyper-IgM immunodeficiency with ectodermal dysplasia (300291), Singh et al. (2009) demonstrated reduced or absent superoxide production after impaired priming and activation of the oligomeric neutrophil NADPH oxidase (NOX; see 300481). The response was particularly weak or absent in IRAK4-deficient PMNs. NEMO-deficient PMNs had a phenotype intermediate between IRAK4-deficient PMNs and normal PMNs. Decreased LPS- and fMLP-induced phosphorylation of p38 (MAPK14; 600289) was observed in both deficiencies. Singh et al. (2009) proposed that decreased activation of NOX may contribute to increased risk of infection in patients with IRAK4 deficiency or NEMO deficiency.


REFERENCES

  1. Day, N., Tangsinmankong, N., Ochs, H., Rucker, R., Picard, C., Casanova, J.-L., Haraguchi, S., Good, R. Interleukin receptor-associated kinase (IRAK-4) deficiency associated with bacterial infections and failure to sustain antibody responses. J. Pediat. 144: 524-526, 2004. [PubMed: 15069404, related citations] [Full Text]

  2. Enders, A., Pannicke, U., Berner, R., Henneke, P., Radlinger, K., Schwarz, K., Ehl, S. Two siblings with lethal pneumococcal meningitis in a family with a mutation in interleukin-1 receptor-associated kinase 4. J. Pediat. 145: 698-700, 2004. [PubMed: 15520784, related citations] [Full Text]

  3. Grazioli, S., Hamilton, S. J., McKinnon, M. I., Del Bel, K. L., Hoang, L., Cook, V. E., Hildebrand, K. J., Junker, A. K., Turvey, S. E. IRAK4 deficiency as a cause for familial fatal invasive infection by Streptococcus pneumoniae. (Letter) Clin. Immun. 163: 14-16, 2016. [PubMed: 26698383, related citations] [Full Text]

  4. Haraguchi, S., Day, N. K., Nelson, R. P., Jr., Emmanuel, P., Duplantier, J. E., Christodoulou, C. S., Good, R. A. Interleukin 12 deficiency associated with recurrent infections. Proc. Nat. Acad. Sci. 95: 13125-13129, 1998. [PubMed: 9789052, images, related citations] [Full Text]

  5. Hoarau, C., Gerard, B., Lescanne, E., Henry, D., Francois, S., Lacapere, J.-J., El Benna, J., Dang, P. M.-C., Grandchamp, B., Lebranchu, Y., Gougerot-Pocidalo, M.-A., Elbim, C. TLR9 activation induces normal neutrophil responses in a child with IRAK-4 deficiency: involvement of the direct PI3K pathway. J. Immun. 179: 4754-4765, 2007. [PubMed: 17878374, related citations] [Full Text]

  6. Ku, C.-L., Picard, C., Erdos, M., Jeurissen, A., Bustamante, J., Puel, A., von Bernuth, H., Filipe-Santos, O., Chang, H.-H., Lawrence, T., Raes, M., Marodi, L., Bossuyt, X., Casanova, J.-L. IRAK4 and NEMO mutations in otherwise healthy children with recurrent invasive pneumococcal disease. J. Med. Genet. 44: 16-23, 2007. [PubMed: 16950813, related citations] [Full Text]

  7. Ku, C.-L., von Bernuth, H., Picard, C., Zhang, S.-Y., Chang, H.-H., Yang, K., Chrabieh, M., Issekutz, A. C., Cunningham, C. K., Gallin, J., Holland, S. M., Roifman, C., and 25 others. Selective predisposition to bacterial infections in IRAK-4-deficient children: IRAK-4-dependent TLRs are otherwise redundant in protective immunity. J. Exp. Med. 204: 2407-2422, 2007. [PubMed: 17893200, images, related citations] [Full Text]

  8. Kuhns, D. B., Long Priel, D. A., Gallin, J. I. Endotoxin and IL-1 hyporesponsiveness in a patient with recurrent bacterial infections. J. Immun. 158: 3959-3964, 1997. [PubMed: 9103466, related citations]

  9. Lavine, E., Somech, R., Zhang, J. Y., Puel, A., Bossuyt, X., Picard, C., Casanova, J. L., Roifman, C. M. Cellular and humoral aberration in a kindred with IL-1 receptor-associated kinase 4 deficiency. J. Allergy Clin. Immun. 120: 948-950, 2007. [PubMed: 17544092, related citations] [Full Text]

  10. Medvedev, A. E., Lentschat, A., Kuhns, D. B., Blanco, J. C. G., Salkowski, C., Zhang, S., Arditi, M., Gallin, J. I., Vogel, S. N. Distinct mutations in IRAK-4 confer hyporesponsiveness to lipopolysaccharide and interleukin-1 in a patient with recurrent bacterial infections. J. Exp. Med. 198: 521-531, 2003. [PubMed: 12925671, related citations] [Full Text]

  11. Picard, C., Puel, A., Bonnet, M., Ku, C.-L., Bustamante, J., Yang, K., Soudais, C., Dupuis, S., Feinberg, J., Fieschi, C., Elbim, C., Hitchcock, R., and 18 others. Pyogenic bacterial infections in humans with IRAK-4 deficiency. Science 299: 2076-2079, 2003. [PubMed: 12637671, related citations] [Full Text]

  12. Picard, C., von Bernuth, H., Ghandil, P., Chrabieh, M., Levy, O., Arkwright, P. D., McDonald, D., Geha, R. S., Takada, H., Krause, J. C., Creech, C. B., Ku, C.-L. Clinical features and outcome of patients with IRAK-4 and MyD88 deficiency. Medicine 89: 403-425, 2010. [PubMed: 21057262, related citations] [Full Text]

  13. Singh, A., Zarember, K. A., Kuhns, D. B., Gallin, J. I. Impaired priming and activation of the neutrophil NADPH oxidase in patients with IRAK4 or NEMO deficiency. J. Immun. 182: 6410-6417, 2009. [PubMed: 19414794, images, related citations] [Full Text]

  14. Takada, H., Ishimura, M., Takimoto, T., Kohagura, T., Yoshikawa, H., Imaizumi, M., Shichijyou, K., Shimabukuro, Y., Kise, T., Hyakuna, N., Ohara, O., Nonoyama, S., Hara, T. Invasive bacterial infection in patients with interleukin-1 receptor-associated kinase 4 deficiency. Medicine 95: e2437, 2016. Note: Electronic Article. [PubMed: 26825884, related citations] [Full Text]

  15. Takada, H., Yoshikawa, H., Imaizumi, M., Kitamura, T., Takeyama, J., Kumaki, S., Nomura, A., Hara, T. Delayed separation of the umbilical cord in two siblings with interleukin-1 receptor-associated kinase 4 deficiency: rapid screening by flow cytometer. J. Pediat. 148: 546-548, 2006. Note: Erratum: J. Pediat. 166: 1550 only, 2015. [PubMed: 16647421, related citations] [Full Text]


Cassandra L. Kniffin - updated : 06/20/2020
Paul J. Converse - updated : 3/1/2011
Paul J. Converse - updated : 2/4/2011
Matthew B. Gross - updated : 1/29/2009
Paul J. Converse - updated : 1/29/2009
Natalie E. Krasikov - updated : 8/10/2004
Creation Date:
Ada Hamosh : 4/7/2003
carol : 01/26/2021
carol : 06/25/2020
ckniffin : 06/20/2020
mgross : 09/05/2014
carol : 6/22/2011
mgross : 3/1/2011
mgross : 2/4/2011
mgross : 2/4/2011
mgross : 1/29/2009
mgross : 1/29/2009
carol : 8/10/2004
terry : 8/10/2004
alopez : 4/7/2003

# 607676

IMMUNODEFICIENCY 67; IMD67


Alternative titles; symbols

IRAK4 DEFICIENCY; IKAK4D
INVASIVE PNEUMOCOCCAL DISEASE, RECURRENT ISOLATED; IPD


Other entities represented in this entry:

INVASIVE PNEUMOCOCCAL DISEASE, PROTECTION AGAINST, INCLUDED

ORPHA: 70592;  


Phenotype-Gene Relationships

Location Phenotype Phenotype
MIM number
Inheritance Phenotype
mapping key
Gene/Locus Gene/Locus
MIM number
12q12 Immunodeficiency 67 607676 Autosomal recessive 3 IRAK4 606883

TEXT

A number sign (#) is used with this entry because of evidence that immunodeficiency-67 (IMD67) is caused by homozygous or compound heterozygous mutation in the gene encoding interleukin-1 receptor-associated kinase-4 (IRAK4; 606883) on chromosome 12q12.


Description

Immunodeficiency-67 (IMD67) is an autosomal recessive primary immunodeficiency characterized by recurrent severe systemic and invasive bacterial infections beginning in infancy or early childhood. The most common organisms implicated are Streptococcus pneumoniae and Staphylococcus aureus; Pseudomonas and atypical Mycobacteria may also be observed. IMD67 is life-threatening in infancy and early childhood. The first invasive infection typically occurs before 2 years of age, with meningitis representing up to 41% of the bacterial infections. The mortality rate in early childhood is high, with most deaths occurring before 8 years of age. Affected individuals have an impaired inflammatory response to infection, including lack of fever and neutropenia, although erythrocyte sedimentation rate (ESR) and C-reactive protein may be elevated. General immunologic workup tends to be normal, with normal levels of B cells, T cells, and NK cells. However, more detailed studies indicate impaired cytokine response to lipopolysaccharide (LPS) and IL1B (147720) stimulation; response to TNFA (191160) is usually normal. Patients have good antibody responses to most vaccinations, with the notable exception of pneumococcal vaccination. Viral, fungal, and parasitic infections are not generally observed. Early detection is critical in early childhood because prophylactic treatment with IVIg or certain antibiotics is effective; the disorder tends to improve naturally around adolescence. At the molecular level, the disorder results from impaired function of selective Toll receptor (see TLR4, 603030)/IL1R (see IL1R1, 147810) signaling pathways that ultimately activate NFKB (164011) to produce cytokines (summary by Ku et al., 2007; Picard et al., 2010; Grazioli et al., 2016).

See also IMD68 (612260), caused by mutation in the MYD88 gene (602170), which shows a similar phenotype to IMD67. As the MYD88 and IRAK4 genes interact in the same intracellular signaling pathway, the clinical and cellular features are almost indistinguishable (summary by Picard et al., 2010).


Clinical Features

Kuhns et al. (1997) reported a 15-year-old girl with a history of recurrent infections since early childhood. She did not have delayed separation of the umbilical cord at birth. Her infections, which were associated with minimal or no febrile response and persistent neutropenia, included pneumococcal meningitis, Neisseria, and Staphylococcus aureus, as well as other infections. She had poor response to LPS and IL1B, but normal response to TNFA, in vivo and in vitro, suggesting a defect in an upstream signaling pathway. In a follow-up report of this patient, Medvedev et al. (2003) noted that her clinical manifestations improved after adolescence.

Haraguchi et al. (1998) described a 3-year-old girl, born of an incestuous relationship, who presented in infancy with recurrent severe infections, including cellulitis, lymphadenitis, septic arthritis, and sepsis due to Staphylococcus aureus and pneumococcus. She did not have fever. Detailed immunologic workup showed deficient production of IL12 (see IL12B, 161561). The patient's peripheral blood mononuclear cells (PBMCs) exhibited normal proliferative responses to antigens and normal immune responses, including in vivo production of antibodies to diphtheria, tetanus, and pneumococcal antigens. Immunoglobulin levels and B-cell and T-cell phenotypes were also normal. In contrast, IL12 p70 heterodimer production was undetectable by using supernatants of the patient's stimulated PBMCs when compared with control cells treated similarly. Although present, IFNG (147570) was reduced, and patient cells did not produce IL12 in response to recombinant IFNG, Staphylococcus aureus, or LPS. Patient cells were able to produce IL2 (147680), IL6 (147620), TNFA (191160), and IFNG after appropriate stimulation. The findings suggested either a defect in the signaling pathways for the activation of IL12B gene expression or an abnormality in IL12B itself.

Picard et al. (2003) described 3 unrelated children, including the child originally reported by Haraguchi et al. (1998), with recurrent infections and poor inflammatory response in whom extracellular, pyogenic bacteria were the only microorganisms responsible for infection. Gram-positive Streptococcus pneumoniae and Staphylococcus aureus were the most frequently found and were the only pathogens identified in 2 patients. Infections began early in life but became less frequent with age, and the patients were well with no treatment at ages 6, 11, and 7 years. All known primary immunodeficiencies were excluded. In particular, the patients had normal serum antibody titers against protein and polysaccharide antigens, including those from S. pneumoniae. None of the patients' monocytes responded to LPS; however, they responded normally to TNF-alpha (191160). The patients did not respond to IL1B, IL18 (600953), or any of the TLR1-6 (see 601194) or TLR9 (605474) ligands, as assessed by activation of NF-kappa-B (see 164011) and p38-MAPK (600289) and induction of IL1B IL6, IL12, TNFA, and IFNG.

In a follow-up of the patients reported by Picard et al. (2003), Day et al. (2004) found that 2 continued to do well, but 1, an 8-year-old girl, was unable to sustain antibody responses to polysaccharide or protein antigens or to a neoantigen-bacteriophage. She continued to have recurring bacterial and fungal infections, eventually requiring intravenous immunoglobulin therapy. They recommended testing for IRAK4 deficiency in patients with recurrent bacterial and fungal infections without sustained antibody response to immunization.

Enders et al. (2004) reported 2 sibs, born of consanguineous Turkish parents, with IMD67. They presented in infancy with recurrent infections, including bronchitis, gastroenteritis, osteomyelitis, and pneumococcal meningitis. Despite treatment, both died, at 14 and 2 months of age. During the infections, both children had a poor inflammatory response without fever, suggesting a deficiency in NFKB-mediated immunity.

Takada et al. (2006) reported 2 Japanese sibs with IMD67. Both had delayed separation of the umbilical cord at 34 to 39 days after birth. The older sib presented in the first years of life with recurrent pneumococcal meningitis and arthritis, which was fatal at age 2. Basic immunologic studies were unremarkable, and he had received several vaccinations without adverse effect; he did not receive pneumococcal vaccination. The younger brother had no apparent infection at 5 months of age. However, in vitro studies showed that patient mononuclear cells had defective IL6 and TNFA production in response to LPS and IL1B. Flow cytometric studies showed impaired intracellular TNFA production in response to LPS, which the authors suggested could be used as a screening method. Takada et al. (2016) reported follow-up of this family, noting that the younger brother from the first report and another affected brother, both of whom had the disorder, had not had invasive bacterial infections due to antimicrobial prophylaxis since early infancy after the diagnosis.

Ku et al. (2007) reported a 7-year-old boy, born to unrelated Hungarian parents, with IMD67. He had routine immunizations with no complications. At age 3 years, he presented with arthritis of the right hip due to pneumococcal infection, followed by pneumococcal meningitis at age 5. During these episodes, he had either no fever or a low-grade fever and low white blood cell counts, indicating a poor inflammatory response. ESR and C-reactive protein were increased. Immunologic workup was essentially normal, although he failed to mount a good antibody response to pneumococcal vaccination; responses to other vaccinations were normal. He had no other bacterial, fungal, or viral infections. Patient cells showed impaired IL6 production in response to IL1B and LPS compared to controls, although response to TNFA was normal. These findings suggested a defect in the TLR (see 603030)-NFKB (see 164011) signaling pathway.

Lavine et al. (2007) reported 3 sibs with IMD67. The first child died at age 5 months due to septic shock associated with Staphylococcus aureus meningitis. The other 2 sibs, who were twins, had recurrent severe systemic infections since early childhood, mainly due to pneumococcus, but also Pseudomonas and atypical Mycobacterium. Both twins had delayed or attenuated signs of inflammation, such as absence of fever and persistent neutropenia. They were treated with IVIg until about age 18 years, but did not have recurrence of the infections as young adults. Immunologic studies showed impaired IL6 production in response to LPS or IL1B compared to controls. There was also some evidence of T-cell dysfunction, including low numbers of CD3+ T cells and variably impaired proliferative responses to antigens. There was a normal antibody response to most vaccinations, but not to pneumococcal vaccine. These findings indicated defects in both the adaptive and innate immune systems, and also suggested that the condition may improve with age.

Ku et al. (2007) reported 28 patients with IMD67. Many of the patients had previously been reported. Most patients developed invasive and often recurrent pneumococcal disease in childhood, but other infections, except for severe Staphylococcal disease, were rare. Although nearly half of the patients died, death occurred only in patients 8 years old and younger. Older patients tended to have remission of the disease. Detailed analysis of patient leukocyte subsets showed that only the TLR3 agonist poly(I:C) could induce production of 11 non-IFN cytokines. The TLR4 agonist, LPS, could induce some responses in myeloid dendritic cells and monocyte-derived dendritic cells. The TLR3 (603029)- and TLR4-interferon-alpha (IFNA; 147660)/beta (IFNB; 147640) pathways were not impaired. Ku et al. (2007) concluded that IRAK4-dependent TLRs and IL1Rs are vital for childhood immunity to pyogenic bacteria, particularly S. pneumoniae, but they are not essential for protective immunity to most infections.

Hoarau et al. (2007) reported a 14-year-old French boy, born of unrelated patients, with IRAK4 deficiency characterized by recurrent infections, osteomyelitis, and cellulitis beginning at age 15 days. Apart from elevated C-reactive protein (CRP; 123260) and very low neutrophil numbers, his immunologic status was normal.

Picard et al. (2010) reported and reviewed the features of 48 patients from 31 kindreds with IMD67, including 36 previously reported patients and 12 new patients. The families originated from several countries; 5 families were consanguineous. In general, immunologic investigations showed normal T and B lymphocytes, NK cells, monocytes, dendritic cells, and Ig levels, although some patients had relatively high levels of certain Ig subsets. These patients had good antibody responses to most vaccinations, although about half had poor response to pneumococcal antigen. Most patients developed early-onset invasive bacterial infections, including meningitis, sepsis, arthritis, osteomyelitis, and deep tissue abscesses. Noninvasive cutaneous or upper respiratory infections were also observed. The most common organisms were Streptococcal pneumoniae, Staphylococcus aureus, and Pseudomonas aeruginosa. Less common organisms included H. influenzae, Shigella, and Neisseria. Affected individuals had an impaired inflammatory response, manifest as poor or absent fever and low leukocyte and neutrophil levels; C-reactive protein levels were variable. Functional studies of patient cells show impaired cytokine responses to TLR and IL1R agonists, with, for example, low IL6 and low TNFA production. Many died of the disease, all before 8 years of age, and most before 2 years. Prophylactic treatment with antibiotics and IVIg was beneficial for survival. Clinical status and outcome improved with age, particularly around adolescence. Picard et al. (2010) noted the narrow susceptibility to certain bacterial infections and emphasized that early diagnosis is critical to initiate treatment.

Grazioli et al. (2016) reported 2 sisters, born of unrelated European Canadian parents, with IMD67 manifest as severe invasive pneumococcal meningitis resulting in death at 2 and 3 years of age. They both had routine immunizations early in life, normal immune cell levels, and no fever during the infections, indicating poor inflammatory responses.

Takada et al. (2016) reported 10 Japanese patients from 6 unrelated families with IMD67. One of the families had previously been reported (Takada et al., 2006); the sibs in that family were treated early and did not have invasive infections. The other 8 patients had severe invasive bacterial infections before the age of 4 years. Seven of them had pneumococcal meningitis, and 5 died of the infection despite early intervention with antibiotic therapy. Four patients had delayed separation of the umbilical cord (later than 21 days). Laboratory studies showed no apparent abnormalities in serum Ig levels, lymphocyte subsets, NK activity, or lymphocyte proliferative response against PHA. However, the patients studied had decreased TNFA production from stimulated monocytes.


Inheritance

The transmission pattern of IMD67 in the families reported by Picard et al. (2003) was consistent with autosomal recessive inheritance.


Molecular Genetics

In 3 patients with IMD67, Picard et al. (2003) identified homozygous loss-of-function mutations in the IRAK4 gene (see 606883.0001-606883.0002). In each case, the mutations were associated with complete deficiency for the kinase. One of the patients was originally reported by Haraguchi et al. (1998).

In a 15-year-old girl with IMD67 (Kuhns et al., 1997), Medvedev et al. (2003) identified compound heterozygous mutations in the IRAK4 gene (606883.0002 and 606883.0003). Both mutations resulted in proteins with intact death domains but truncated kinase domains, precluding expression of full-length IRAK4 and conferring a recessive phenotype.

In a patient, born of consanguineous Turkish parents, with IMD67, Enders et al. (2004) identified a homozygous frameshift mutation (c.573delA; 606883.0008) in the IRAK4 gene. No material was available for further analysis, but the mutation segregated with the disorder in the family. A similarly affected sib had died of the disease, but no DNA from this sib was available.

In 2 Japanese sibs with IMD67, Takada et al. (2006) identified a homozygous frameshift mutation in the IRAK4 gene (606883.0009). The mutation segregated with the disorder in the family.

In a 7-year-old boy born of unrelated Hungarian parents, Ku et al. (2007) found that IMD67 was related to compound heterozygosity for 2 mutations in the IRAK4 gene, located in intron 10 (c.1189-1G-T, 606883.0004 and c.1188+520A-G, 606883.0005). The authors noted that this patient was the first in whom noncoding mutations in the IRAK4 gene had been found.

In 2 sibs with IMD67, Lavine et al. (2007) identified a homozygous nonsense mutation in the IRAK4 gene (Q293X; 606883.0002). The mutation segregated with the disorder in the family.

In a 14-year-old French boy with IMD67, Hoarau et al. (2007) identified compound heterozygous mutations in the IRAK4 gene (see 606883.0006 and 606883.0007). Stimulation of the patient's PMNs with TLR agonists revealed the absence of IRAK1 (300283) phosphorylation and impaired PMN responses. However, responses to the TLR9 agonist CpG were normal, except for cytokine production. Impairment of TLR9 responses was observed after pretreatment with PI3K (see 601232) inhibitors. Hoarau et al. (2007) proposed that there may be an alternative TLR9 pathway leading to PI3K activation independently of the classical MYD88 (602170)-IRAK4 pathway. They suggested that this alternative pathway may play a role in control of infections by microorganisms other than pyogenic bacteria in patients with IRAK4 deficiency.

In 9 patients from 5 unrelated Japanese families with IMD67, Takada et al. (2016) identified a homozygous frameshift mutation in the IRAK4 gene (606883.0009). Another affected Japanese patient (patient 4) was compound heterozygous for that mutation and a nonsense mutation. The findings suggested that the frameshift mutation is a founder mutation in the Japanese population.


Pathogenesis

By studying responses to the TLR4 ligand, LPS, and to the bacterial chemoattractant, fMLP, in PMNs from 1 patient with IRAK4 deficiency and 3 patients with NEMO (300248) deficiency causing X-linked hyper-IgM immunodeficiency with ectodermal dysplasia (300291), Singh et al. (2009) demonstrated reduced or absent superoxide production after impaired priming and activation of the oligomeric neutrophil NADPH oxidase (NOX; see 300481). The response was particularly weak or absent in IRAK4-deficient PMNs. NEMO-deficient PMNs had a phenotype intermediate between IRAK4-deficient PMNs and normal PMNs. Decreased LPS- and fMLP-induced phosphorylation of p38 (MAPK14; 600289) was observed in both deficiencies. Singh et al. (2009) proposed that decreased activation of NOX may contribute to increased risk of infection in patients with IRAK4 deficiency or NEMO deficiency.


REFERENCES

  1. Day, N., Tangsinmankong, N., Ochs, H., Rucker, R., Picard, C., Casanova, J.-L., Haraguchi, S., Good, R. Interleukin receptor-associated kinase (IRAK-4) deficiency associated with bacterial infections and failure to sustain antibody responses. J. Pediat. 144: 524-526, 2004. [PubMed: 15069404] [Full Text: https://doi.org/10.1016/j.jpeds.2003.11.025]

  2. Enders, A., Pannicke, U., Berner, R., Henneke, P., Radlinger, K., Schwarz, K., Ehl, S. Two siblings with lethal pneumococcal meningitis in a family with a mutation in interleukin-1 receptor-associated kinase 4. J. Pediat. 145: 698-700, 2004. [PubMed: 15520784] [Full Text: https://doi.org/10.1016/j.jpeds.2004.06.065]

  3. Grazioli, S., Hamilton, S. J., McKinnon, M. I., Del Bel, K. L., Hoang, L., Cook, V. E., Hildebrand, K. J., Junker, A. K., Turvey, S. E. IRAK4 deficiency as a cause for familial fatal invasive infection by Streptococcus pneumoniae. (Letter) Clin. Immun. 163: 14-16, 2016. [PubMed: 26698383] [Full Text: https://doi.org/10.1016/j.clim.2015.12.007]

  4. Haraguchi, S., Day, N. K., Nelson, R. P., Jr., Emmanuel, P., Duplantier, J. E., Christodoulou, C. S., Good, R. A. Interleukin 12 deficiency associated with recurrent infections. Proc. Nat. Acad. Sci. 95: 13125-13129, 1998. [PubMed: 9789052] [Full Text: https://doi.org/10.1073/pnas.95.22.13125]

  5. Hoarau, C., Gerard, B., Lescanne, E., Henry, D., Francois, S., Lacapere, J.-J., El Benna, J., Dang, P. M.-C., Grandchamp, B., Lebranchu, Y., Gougerot-Pocidalo, M.-A., Elbim, C. TLR9 activation induces normal neutrophil responses in a child with IRAK-4 deficiency: involvement of the direct PI3K pathway. J. Immun. 179: 4754-4765, 2007. [PubMed: 17878374] [Full Text: https://doi.org/10.4049/jimmunol.179.7.4754]

  6. Ku, C.-L., Picard, C., Erdos, M., Jeurissen, A., Bustamante, J., Puel, A., von Bernuth, H., Filipe-Santos, O., Chang, H.-H., Lawrence, T., Raes, M., Marodi, L., Bossuyt, X., Casanova, J.-L. IRAK4 and NEMO mutations in otherwise healthy children with recurrent invasive pneumococcal disease. J. Med. Genet. 44: 16-23, 2007. [PubMed: 16950813] [Full Text: https://doi.org/10.1136/jmg.2006.044446]

  7. Ku, C.-L., von Bernuth, H., Picard, C., Zhang, S.-Y., Chang, H.-H., Yang, K., Chrabieh, M., Issekutz, A. C., Cunningham, C. K., Gallin, J., Holland, S. M., Roifman, C., and 25 others. Selective predisposition to bacterial infections in IRAK-4-deficient children: IRAK-4-dependent TLRs are otherwise redundant in protective immunity. J. Exp. Med. 204: 2407-2422, 2007. [PubMed: 17893200] [Full Text: https://doi.org/10.1084/jem.20070628]

  8. Kuhns, D. B., Long Priel, D. A., Gallin, J. I. Endotoxin and IL-1 hyporesponsiveness in a patient with recurrent bacterial infections. J. Immun. 158: 3959-3964, 1997. [PubMed: 9103466]

  9. Lavine, E., Somech, R., Zhang, J. Y., Puel, A., Bossuyt, X., Picard, C., Casanova, J. L., Roifman, C. M. Cellular and humoral aberration in a kindred with IL-1 receptor-associated kinase 4 deficiency. J. Allergy Clin. Immun. 120: 948-950, 2007. [PubMed: 17544092] [Full Text: https://doi.org/10.1016/j.jaci.2007.04.038]

  10. Medvedev, A. E., Lentschat, A., Kuhns, D. B., Blanco, J. C. G., Salkowski, C., Zhang, S., Arditi, M., Gallin, J. I., Vogel, S. N. Distinct mutations in IRAK-4 confer hyporesponsiveness to lipopolysaccharide and interleukin-1 in a patient with recurrent bacterial infections. J. Exp. Med. 198: 521-531, 2003. [PubMed: 12925671] [Full Text: https://doi.org/10.1084/jem.20030701]

  11. Picard, C., Puel, A., Bonnet, M., Ku, C.-L., Bustamante, J., Yang, K., Soudais, C., Dupuis, S., Feinberg, J., Fieschi, C., Elbim, C., Hitchcock, R., and 18 others. Pyogenic bacterial infections in humans with IRAK-4 deficiency. Science 299: 2076-2079, 2003. [PubMed: 12637671] [Full Text: https://doi.org/10.1126/science.1081902]

  12. Picard, C., von Bernuth, H., Ghandil, P., Chrabieh, M., Levy, O., Arkwright, P. D., McDonald, D., Geha, R. S., Takada, H., Krause, J. C., Creech, C. B., Ku, C.-L. Clinical features and outcome of patients with IRAK-4 and MyD88 deficiency. Medicine 89: 403-425, 2010. [PubMed: 21057262] [Full Text: https://doi.org/10.1097/MD.0b013e3181fd8ec3]

  13. Singh, A., Zarember, K. A., Kuhns, D. B., Gallin, J. I. Impaired priming and activation of the neutrophil NADPH oxidase in patients with IRAK4 or NEMO deficiency. J. Immun. 182: 6410-6417, 2009. [PubMed: 19414794] [Full Text: https://doi.org/10.4049/jimmunol.0802512]

  14. Takada, H., Ishimura, M., Takimoto, T., Kohagura, T., Yoshikawa, H., Imaizumi, M., Shichijyou, K., Shimabukuro, Y., Kise, T., Hyakuna, N., Ohara, O., Nonoyama, S., Hara, T. Invasive bacterial infection in patients with interleukin-1 receptor-associated kinase 4 deficiency. Medicine 95: e2437, 2016. Note: Electronic Article. [PubMed: 26825884] [Full Text: https://doi.org/10.1097/MD.0000000000002437]

  15. Takada, H., Yoshikawa, H., Imaizumi, M., Kitamura, T., Takeyama, J., Kumaki, S., Nomura, A., Hara, T. Delayed separation of the umbilical cord in two siblings with interleukin-1 receptor-associated kinase 4 deficiency: rapid screening by flow cytometer. J. Pediat. 148: 546-548, 2006. Note: Erratum: J. Pediat. 166: 1550 only, 2015. [PubMed: 16647421] [Full Text: https://doi.org/10.1016/j.jpeds.2005.12.015]


Contributors:
Cassandra L. Kniffin - updated : 06/20/2020
Paul J. Converse - updated : 3/1/2011
Paul J. Converse - updated : 2/4/2011
Matthew B. Gross - updated : 1/29/2009
Paul J. Converse - updated : 1/29/2009
Natalie E. Krasikov - updated : 8/10/2004

Creation Date:
Ada Hamosh : 4/7/2003

Edit History:
carol : 01/26/2021
carol : 06/25/2020
ckniffin : 06/20/2020
mgross : 09/05/2014
carol : 6/22/2011
mgross : 3/1/2011
mgross : 2/4/2011
mgross : 2/4/2011
mgross : 1/29/2009
mgross : 1/29/2009
carol : 8/10/2004
terry : 8/10/2004
alopez : 4/7/2003